Metrobactin Tablets 250mg (Pack of 250)

Target species Dogs and cats Indications for use Treatment of gastrointestinal tract infections caused by Giardia spp. and Clostridia spp. (i.e. C. perfringens or C. difficile). Treatment of infections of the urogenital tract, oral cavity, throat and skin caused by obligate anaerobic bacteria (e.g. Clostridia spp.) susceptible to metronidazole. Contraindications Do not use in case of hepatic disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Special precautions for use in animals Due to the likely variability (time, geographical) in the occurrence of metronidazole resistant bacteria, bacteriological sampling and susceptibility testing are recommended. Whenever possible, the product should only be used based on susceptibility testing. Official, national and regional anitmicrobial policies should be taken into account when the veterinary medicinal product is used. Especially afer prolonged treatment with metronidazole neurological signs could occur. Special precautions to be taken by the person administering the veterinary medicinal product to animals Metronidazole has confirmed mutagenic and genotoxic properties in laboratory animals as well as in humans. Metronidazole is a confirmed carcinogen in laboratory animals and has possible carcinogenic effects in humans. However, there is inadequate evidence in humans for the carcinogenicity of metronidazole. Impervious gloves should be worn during administration of the product to avoid skin contact with the product. To avoid accidental ingestion, particularly by a child, unused part-tablets should be returned to the open blister space and inserted back into the carton. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Wash hands thoroughly after handling the tablets. Adverse reactions The following adverse reactions may occur after administration of metronidazole: vomiting, hepatotoxicity, neutropenia and neurologic signs. Use during pregnancy and lactation Studies in laboratory animals have shown inconsistent results with regard to teratogenic/embryotoxic effects of metronidazole. Therefore, use of this product during pregnancy is not recommended. Metronidazole is excreted in milk and use during lactation is therefore not recommended. Interactions Metronidazole may have an inhibitory effect on the degradation of other drugs in the liver, such as phenytoin, cyclosporine and warfarin. Cimetidine may decrease the hepatic metabolism of metronidazole resulting in increased serum concentration of metronidazole. Phenobarbital may increase hepatic metabolism of metronidazole resulting in decreased serum concentration of metronidazole.